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Abstract. The merozoite surface protein-1 (MSP1) is the most studied malaria blood-stage vaccine candidate.
Lymphokines such as interferon gamma (IFN-) and interleukin 4 (IL-4) may mediate blood-stage specific protection.
Here we identify Plasmodium falciparum MSP1 T-cell epitopes capable of rapid induction of IFN- and/or IL-4 from
peripheral blood mononuclear cells of East and West African donors. Both allelic forms of these novel MSP1 T-cell
epitopes were stimulatory. An unusually high numbers of Gambian responders ( 80%) to these epitopes were
observed, suggesting that MSP1 reactivity may have been underestimated previously in this population. Surprisingly,
IFN- responses to allelic T-cell epitopes failed to correlate with differential antigenic exposure in The Gambia
compared to Kenya. These results suggest an unexpected level of immunoregulation of IFN- response with variable
allelic T-cell reactivity independent of the level of antigenic exposure. Further analysis of the mechanisms determining
this response pattern may be required if vaccines are to overcome this allelic reactivity bias in malaria-exposed
populations.
INTRODUCTION
The success of an effective malaria blood-stage vaccine
may depend on its ability to induce both cellular and hu-
moral immunity.1 A major blood-stage vaccine candidate is
the merozoite surface protein-1 (MSP1) of Plasmodium fal-
ciparum.2 Antibodies to MSP1 can mediate murine, primate
and human blood-stage immunity.3–8 The role of blood-stage
specific human T cells is less clear, although some T-cell
epitopes have been defined,9–15 and T-cell proliferative and
interferon gamma (IFN-) responses may be associated with
reduced susceptibility to clinical malaria.16,17 The full range
of T-cell epitopes present in MSP1 is unknown.
It is unclear which cellular immune mechanisms protect
against human blood-stage malaria. In Plasmodium chabaudi
infection, T-helper 1 (Th1) followed by T-helper 2 (Th2)
responses both contribute to protection.18–20 Naturally-ex-
posed populations have IFN- secreting MSP1 specific T
cells,11,16,17 but it is unclear whether they may also have IL-
4 producing T cells. Previous attempts to measure IL-4 pro-
duction by ELISA may have been unsuccessful due to the
low sensitivity of this assay.11 The enzyme-linked immuno-
spot (ELISPOT) assay is 20- to 200-fold more sensitive than
ELISA.21,22 ELISPOT assays detect only circulating effector
T cells capable of rapid (16–24 hr) lymphokine secretion,
and thus do not rely on in vitro expansion of antigen specific
T cells. Early T-cell lymphokine secretion may play a role
in the subsequent Th1/Th2 bias of blood-stage immunity.
Here Th1 and Th2 responses were assessed in ELISPOT
assays of MSP1 peptides that differed between the MAD20
and WELLCOME types and were predicted to bind protec-
tive African HLA class II alleles. Novel T-cell epitopes were
identified which were frequently recognized by malaria-ex-
posed donors. A Th1 bias of responses was confirmed for
the majority of these T-cell epitopes.
MSP1 is a dimorphic protein, represented by two allelic
types, MAD20 and WELLCOME.23 Parasite epidemiological
studies show different distributions of these allelic strains in
West24 compared to East Africa.25 It was therefore of interest
to compare the allelic MSP1 T-cell reactivity patterns be-
tween West and East Africa. Whereas IL-4 responses to spe-
cific T-cell epitopes reflected the epidemiological parasite
prevalence in The Gambia, IFN- responses did not, either
in The Gambia or Kenya, suggesting that IFN- and IL-4
production were independently regulated. Moreover, these
results suggest that immune selection may act on MSP1
through a selected T-cell effector activity. These findings
have important implications for our understanding of host-
parasite interactions and may be of direct relevance to the
design of vaccines which aim to boost protective responses
in malaria endemic populations.
MATERIALS AND METHODS
Study area and volunteers. Malaria-exposed adults were
from the villages of Brefet, Jali, and Berending in The Gam-
bia, West Africa and from the villages around Kilifi in Ken-
ya, East Africa. These studies were approved by the Ethical
Committee of The Gambia Medical Research Council and
the Kenya Medical Research Institute. All adult subjects
were aged between 18–60 years-old. Thick and thin blood
films were prepared at the time of bleeding, stained with
Giemsa, and examined by microscopy for the presence of
circulating malaria parasites. All malaria-exposed donors
were clinically healthy and parasite-negative by microscopy
at the time of blood sampling.
High malaria transmission in The Gambia commences
shortly after the start of the rainy season and occurs between
August and November.26 Gambian samples were collected
both before (March to April, 1998) and after the wet season
(October to November, 1998). No statistical differences in
Gambian IFN- reactivity patterns between samples collect-
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ed during the wet and dry seasons were observed (data not
shown). Malaria transmission in Kenya is highest during and
following the long rains (March to May) with a second peak
of transmission occurring after the short rains in October to
December.27 Kenyan samples were taken after the wet season
(July to August, 1999). Malaria-unexposed donors were used
as negative controls for IFN- and IL-4 ELISPOT detection
assays. These were clinically healthy European-Caucasian
volunteers aged between 21–50 years from Oxford, UK, who
had not traveled to a malaria-endemic country.
Blood collection and cell preparations. After informed
consent, 20 ml of venous blood was collected into heparin.
Cells were separated by density gradient centrifugation on
Lymphoprep (Pharmacia, Oslo, Norway) at 800 g for 20
min. Peripheral blood mononuclear cells (PBMCs) were col-
lected from the blood-ficoll interface and washed three times
in RPMI-1640 medium (Sigma, Irvine, UK). PBMCs were
resuspended at 4106 per ml in RPMI-1640 medium sup-
plemented with 5% heat inactivated human AB serum, 2
MM glutamine (Gibco, Paisley, UK), 100 g per ml strep-
tomycin (Gibco) and 100 units per ml penicillin (Gibco)
(RN5) prior to use in ELISPOT assays.
MSP1 peptides. HLA-DRB1*1302 (DR1302) and HLA-
DRB1*1301 (DR1301) alleles are identical except for a gly-
cine to valine change at position 86 of the HLA-DR chain
which affects the preference for particular hydrophobic pep-
tide residues.28 DR1302, but not DR1301, was shown to be
protective against severe malaria in The Gambia.29 Hence,
DR1302 and DR1301 alleles may present different peptides
to CD4 T cells. Thus, a ‘‘subtracted motif’’ which char-
acterized peptides that could bind to the allelic motif of
DR1302 but not to DR1301 was defined. By contrast in Ken-
ya, HLA-DRB1∗0101 (DR1) but not DR1302 or DR1301
was shown to be protective against severe malaria (Yates
SN, unpublished data). Two selection criteria for choosing
MSP1 peptides were employed: one based on the peptide-
binding motifs of the two protective class II alleles, HLA-
DRB1*0101 (DR1) and DR1302; the other based on this
‘‘subtracted motif.’’ Using a computer prediction algorithm30
which predicted potential T-cell epitopes that differed be-
tween two major allelic types of MSP1, MAD20 and WELL-
COME type, a total of 26 allelic variant peptides were syn-
thesized (Table 1). This computer program utilizes pool se-
quence data from HLA class-II proteins and scans the MSP1
protein for candidate epitopes that fit the HLA class-II pep-
tide motif. A probability of being processed and presented
(PPP) algorithm score is assigned to each amino acid of the
protein which determines the probability of a 15-mer peptide
beginning with that amino acid to be naturally processed and
presented. All peptides were purified by high-performance
liquid chromatography (HPLC) and purity ranged from 
80% to  95%. Peptides were reconstituted in sterile phos-
phate-buffered saline (PBS) and used at a pre-determined
optimal culture concentration of 25 g/ml. When tested in
pools each peptide was used at 25 g/ml. Table 1 shows the
composition of the peptide pools. Peptides were grouped into
non-overlapping pools of 2 or 3 peptides based on their al-
lelic type (MAD20 or WELLCOME) and their peptide motif
to either DR1 or DR1302.
Control antigens. The mitogen phytohemoglutin (PHA)
(Wellcome Pharmaceuticals, Stevenage, UK) and two recall
antigens, tetanus toxoid (TT) (Evans Biomedical, Horsham,
UK), and purified protein derivative (PPD) from Mycobac-
terium bovis (Statens Serum Institut, Copenhagen, Denmark)
were used as positive controls antigens. PHA was used at 1
g/ml and the two recall antigens were used in cultures at
10 g/ml.
Ex-vivo ELISPOT assays. Ninety-six well polyvinylide-
ne difluroide (PVDF) backed plates (MAIP S45, Millipore,
Molsheim, France) were coated with 15 g/ml of monoclo-
nal anti-human IFN- (1-D1K), or IL-4 (IL-4-I), or IL-10
(9-D7) antibodies (all from Mabtech, Nacka, Sweden) for 3
hours at room temperature (RT) or overnight at 4C. The
plates were then washed 5 times with sterile PBS pH 7.4,
(Sigma) and then blocked for 1 hour at RT with RPMI-1640
supplemented with 10% heat inactivated human AB serum
(RN10). PBMCs were plated at 100 l (4105 cells) per
well. MSP1 peptides, peptide pools, or antigens were added
to each well. The plates were incubated at 37C in 5% CO2/
95% air (18 hr for IFN- detection, 24 hr for IL-4 and IL-
10 detection). Plates were then processed by washing 4 times
in PBS with 0.05% Tween-20 (Sigma) and 2 times with PBS.
One microgram per milliliter of the second biotinylated
monoclonal antibody of either IFN- (7-B6-1-Biotin), IL-4
(IL-4-II-Biotin) or IL-10 (12G8-Biotin) (all from Mabtech)
was added and incubated for 2 hours at RT. The plates were
washed as described above and incubated for 1 hour at RT
with 1 g/ml strepavidin alkaline phosphatase (ALP). These
were washed again and developed with the ALP conjugate
substrate kit (Biorad, Hercules, CA). Individual cytokine-
producing cells within each well leave a ‘‘footprint’’ or spot
which is visualized with the aid of a dissecting microscope
(magnification  2). Data is presented as spot-forming-units
(SFU) per million PBMC.
A response was considered positive if the probability of
a cell forming a spot was higher in the test well compared
to the negative-control well (P  0.05). The significance test
was a chi-squared comparison of the odds ratios of numbers
of lymphokine-positive cells in the test well and the control
well.31 This method of determining a significant positive
ELISPOT response is as powerful as non-parametric or para-
metric comparisons of the means or medians of several rep-
licate wells. The null hypothesis tested by our significance
test is: the probability of a cell forming a spot in the control
well is the same as the probability of a cell forming a spot
in the well with peptide. The null hypothesis is rejected at
the 95% confidence limit if there are at least  5 spots in
the test well than in the control well. This significant cut-off
value above background spots higher than zero increased
based on a binomial distribution assuming 4  105 cells per
well. Similar significant values were obtained if a Poisson
model was used.
Molecular detection of MSP1 allelic strain distribution.
DNA samples of Gambian29 and Kenyan (Yates SN, unpub-
lished data) children with clinical malaria were collected as
part of an earlier case-control study of malaria. Part of the
P. falciparum MSP1 gene (283 base pairs [bp]) correspond-
ing to the allelic variant epitope pair, M3/M4 was amplified
by polymerase chain reaction (PCR) with biotinylated prim-
ers (5	 to 3	): TACAATAAACAATTACAAGAAGC and
TTAAATAATATTCTAAT-TCAAGTGG. Polymerase chain
reaction was carried out in 16 mM (NH4)2SO4, 67 mM tris
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FIGURE 1. Percentage positive IFN- lymphokine responders of 22 malaria-exposed donors reacting to the panel of MSP1 peptides.
Peripheral blood mononuclear cells from adult Gambians were stimulated separately with either MSP1 allelic variant peptide (MAD20 or
WELLCOME) in a 16 hr ex-vivo IFN- release assay. Positive IFN- enzyme-linked immunospots (ELISPOTs) detect a precursor frequency
of  1 per 1105 responding cells (P  0.05). The MSP1 protein is divided into 17 blocks based on amino-acid homology between dimorphic
types.23 Conserved (), semi-conserved (shaded [f]) and polymorphic () blocks are shown. Untested MSP1 allelic variant peptides are
represented by an asterisk.
HCl (pH 8.8), 0.01% Tween 20, 0.5 mM MgCl2, and 0.5
mM spermidine, with deoxynucleotide triphosphates (0.2
mM) and a 0.5 mM concentration of each primer, for an
initial denaturation step of 94C for 1,080 sec, followed by
32 cycles each of 10 sec at 94C, 30 sec at 48C, and 60 sec
at 72C. To obtain single stranded PCR products, 5 l of
PCR product was denatured in equal volume of 1.6% sodium
hydroxide solution for 5 min at room temperature. The de-
natured samples were then transferred to a pre-washed stre-
pavidin coated microtitration plates (Wallac Oy, Turku, Fin-
land).
The molecular detection of M3/M4 allelic types was by
allele-specific hybridization of Europium (Eu) labeled M3
(MAD20) or Samarium (Sm) labeled M4 specific probe to
single-stranded PCR products immobilized on pre-washed
strepavidin-coated microtitration plates (Wallac Oy). To ob-
tain single-stranded PCR products, 5 l of PCR product was
denatured by an equal volume of 1.6% sodium hydroxide
solution for 5 min at room temperature and added to 100 l
of DELFIA assay buffer (Wallac Oy), containing 2 ng Eu-
labeled M3 (MAD20) specific probe (5	 to 3	), Eu-GAA-
GATATAGATAAA and 5 ng Sm-labeled M4 (WELL-
COME) specific probe (5	 to 3	), Sm-GATAAGATAAAT-
GAA per well. Plates were incubated for 1hr at room tem-
perature on a plate shaker and washed 6 times in Wallac
wash solution to remove excess unbound probes. 200 l of
Wallac enhancement solution was added per well to activate
the fluorescence labeled probes and the plates were shaken
for a further 45 min at room temperature. Fluorescent signals
from simultaneously hybridized Eu- and Sm-labeled specific
probes were then measured and quantified using a time-re-
solved 1234 Wallac Fluorometer. The number of samples
that hybridized to Eu (MAD20) or Sm (WELLCOME)
probes was expressed as a percentage of the total number of
Gambian (234 total) and Kenyan (212 total) samples. Similar
results were obtained typing the same Gambian donors by
standard dot-blot hybridization with allele-specific oligonu-
cleotide probes32 (data not shown).
RESULTS
Peripheral-blood mononuclear cells from 22 malaria-ex-
posed Gambian adults were tested in IFN- ELISPOT re-
sponses to MSP1 peptides (Figure 1). Table 1 lists the pep-
tides, selected on the basis of sequence differences between
MAD20 and WELLCOME types and predicted binding to
protective African HLA class II alleles HLA-DRB1*1302
(DR1302) and HLA-DRB1*0101 (DR1).29 The majority (18
of 22) of individuals gave an IFN- response to at least one
MSP1 peptide. A minimum of four individuals responded to
each of these MSP1 peptides. This unexpectedly high level
of reactivity was unlikely to be due to stimulation of naive
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TABLE 1
Panel of MSP1 allelic variant (MAD20, top, and WELLCOME, bottom) peptide pairs used in malaria-exposed donors in West and East Africa.
Peptides were grouped into nonoverlapping peptide pools, P1 to P8. Peptide pools P1 to P4 correspond to the MAD20 allele, whereas P5
to P8 correspond to the WELLCOME allele. Amino acid positions are taken from Miller and others.56 MSP1 MAD20 peptides with the
DR1 motif were in P1 and P2, and WELLCOME peptides with DR1 motifs were in P5 and P6. MAD20 peptides with the DR1302 motif
were in P3 and P4, and WELLCOME peptides with DR1302 motifs were in P7 and P8 (M37, M34). Peptides M3 through M8 were tested
individually both in The Gambia and Kenya
No. Position Sequences Peptide pools
MAD20
M3
M5
M7
M19
M21
M23
M25
M28
M30
M32
M36
M38
M41
344–357
310–328
1538–1550
268–282
471–485
524–538
698–712
1429–1443
1465–1479
444–457
1185–1199
464–477
519–532
N E N I K K L L E D I D K I
L Y Q A Q Y N L F I Y N K Q L Q E A H
D Y L I N L K A K I N D C
K M E D Y I K K N K T T I A N
N P D T K E K I N E K I I T D
S K K D Y E E L L E K F Y E M
K P E P Y Y L I V L K K E V D
I I E D S F K L L N S E Q K N
E G I S Y Y E K V L A K Y K D
I V Y P L P L T D I H N S L
D N Y A N L E K F R A L S K I
N S Y G D L M P D T K E K
E D Y E K S K K D Y E E L L
P1
P1
P2
P2
P3
P3
P4
P4
WELLCOME
M4
M6
M8
M20
M22
M24
M27
M29
M31
M34
M37
M39
M42
344–357
310–328
1538–1550
268–282
471–485
524–538
698–712
1429–1443
1465–1479
444–457
1185–1199
464–477
519–532
N E N I K E L L D K I N E I
L Y Q A Q Y D L S I Y N K Q L E E A H
L F V I H L E A K V L N V
K M E D Y I K K N K K T I E N
N P F D Y T K E P S K N I Y T
I T K E Y E K L L N E I Y D S
K Q E P Y Y L I V L K K E I D
V V K D P Y K F L N K E K R D
D V L G Y Y K I L S E K Y K S
V T Y P L S Y N D I N N A L
D N Y A S L E N F K V L S K L
N S F G D L I N P F D Y T K
K S L N D I T K E Y E K L L
P5
P5
P6
P6
P6
P7
P7
P8
P8
T cells, since malaria-naive donors (n 
 25) did not have
IFN- reactivity to these MSP1 peptides (data not shown).
IFN- T cell responses in Gambian donors were found dis-
tributed throughout the MSP1 protein, with no immunodom-
inant regions (Figure 1).
MSP1 is a dimorphic protein with allelic types designated
MAD20 and WELLCOME.23 Seroepidemiological studies in
The Gambia have shown a stable parasite distribution over
time with MAD20 at 95% and WELLCOME at 5%.16,24,33
However, the MSP1 dimorphic epitopes identified here were
recognized overall to a similar degree in Gambian donors;
MAD20 responses: 36.8%  2.6 standard error (SE),
WELLCOME responses: 28.4%  4.6 SE. This reactivity
pattern was surprising given the marked excess of the
MAD20 allele (95%) in The Gambia.24 Molecular typing of
MSP1 allelic strain distribution using the sequence-encoding
variant peptides M3 and M4 in block 3 of the gene in 
200 Gambians with clinical malaria confirmed the high prev-
alence of MAD20 (MAD20: 88%, WELLCOME: 12%).
Heterogeneity was observed in the prevalence of IFN re-
sponses to MAD20 or WELLCOME for different MSP1 al-
lelic T-cell epitope pairs. Thus, in the M5/M6 region, IFN-
 responses to the abundant MAD20 parasite form were
prevalent (MAD20: 65% versus WELLCOME: 35%),
whereas the adjacent allelic pair M3/M4 showed equal re-
activity to both forms. Surprisingly, the allelic pair M7/M8
showed higher prevalence of responses to the rare WELL-
COME strain represented by M8 (M7: 25% versus M8:
75%). All epitopes selected on the basis of peptide motifs
to DR1 (e.g., M3/M4), DR1302 (e.g., M5/M6) or the ‘‘sub-
tracted motif’’ (e.g., M7/M8) could bind to varying degrees
to DR1, DR7, DR1301, DR1302, and DR1501 in peptide
binding assays (data not shown). Thus, these unusual allelic
reactivity patterns were unlikely to be due to lack of binding
to HLA-DR.
It was possible that T-cell responses to the MAD20 epi-
tope variant were underestimated by assessing only IFN-,
a characteristic Th1 lymphokine. Therefore, the allelic pairs
of M3/M4, M5/M6, and M7/M8 were used to assess in par-
allel both early IFN- and IL-4 production in a further 14
malaria-exposed adults in The Gambia (Figure 2 and Table
2). In general, fewer donors produced IL-4 (6 of 14 individ-
uals) to these MSP1 epitopes compared to IFN- (12 of 14
individuals). Malaria-naive donors (n 
 10) tested in similar
IL-4 ELISPOT assays did not react to these allelic peptide
pairs (data not shown). Individual donors could respond to
different MSP1 epitopes either by IL-4 or IFN-. Thus, T
cell release of IL-4 did not preclude the ability of a donor
to respond by IFN- (Figure 2). Indeed, 58% (7 of 12 pos-
itive) of total IL-4 responses also had IFN- responses to
the same epitopes. Analysis of IFN- and IL-4 reactivity in
all Gambian donors showed an average higher IFN- (49%)
reactivity to MSP1 allelic variant epitopes compared to IL-
4 (14%) (t-test, P  2105) (Table 2).
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FIGURE 2. Influence of MSP1 allelic variants on ex-vivo IFN- responses in a malaria-exposed donor in The Gambia. Peripheral blood
mononuclear cells (PBMC) of a malaria-exposed donor, Donor Gam01 were tested in parallel ex-vivo IFN- and IL-4 enzyme-linked immu-
nospot (ELISPOT) assay to the panel of MSP1 peptides. Positive IFN- () and IL-4 () producing T cells were represented as spot-forming
units (SFU) per million PBMC. Purified protein derivative (PPD) and tetanus toxoid (TT) are respectively T-helper 1 (Th1) and T-helper 2
(Th2) positive control antigens. Significant (P  0.05) lymphokine responses are marked with asterisks.
FIGURE 3A. Influence of MSP1 peptide pools and allelic variant peptide pairs in malaria-exposed donors in Kenya. Peripheral-blood
mononuclear cells of 7 malaria-exposed Kenyan donors, Donors 1–7 were tested in parallel rapid IFN- (left) and IL-4 (right) enzyme-linked
immunospot (ELISPOT) assay to MSP1 peptide pools, P1 to P8 (See Table 1). Lymphokine responses were expressed as positive spot-forming
units (SFU) per million less the control SFU. Only significant (P  0.05) responses were marked with an asterisk.
The analysis of the limited number of IL-4-specific re-
sponses detected suggested that they may reflect the MAD20
prevalence of parasites (Table 2). This contrasted with IFN-
 reactivity. Thus, IFN- and IL-4 production to allelic-var-
iant epitopes may be independently regulated. However, total
T-cell responsiveness (IFN- and IL-4) still failed to reflect
the higher MAD20 prevalence for allelic pairs M3/M4 and
M7/M8.
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TABLE 2
Summary of IFN- and IL-4 positive responders to MSP1 allelic variant peptide pairs (M3/M4, M5/M6, and M7/M8) in malaria-exposed
donors in The Gambia
IFN- reactivity IL-4 reactivity
M3/M4
Peptide M3
Peptide M4
Specific (MAD20 versus WELLCOME)†
Both variants‡
20/45 (44%)*
24/45 (53%)*
17% versus 31%
52%
3/14 (21%)*
2/14 (14%)*
50% versus 25%
25%
M5/M6
Peptide M5
Peptide M6
Specific (MAD20 versus WELLCOME)†
Both variants‡
24/40 (60%)*
19/40 (48%)*
30% versus 11%
59%
2/14 (14%)*
0/14 (0%)*
100% versus 0%
0%
M7/M8
Peptide M7
Peptide M8
Specific (MAD20 versus WELLCOME)†
Both variants‡
16/44 (36%)*
23/44 (52%)*
9% versus 39%
52%
3/14 (21%)*
2/14 (14%)*
33% versus 0%
67%
* Percentages shown indicate the percentage of positive responders in each group.
† Percentage of specific responses induced by either the AMD20 or the WELLCOME variant from the total number of positive responders.
‡ Percentage of responses induced to both the MAD20 and the WELLCOME variant from the total number of positive responders.
FIGURE 3B. Peripheral blood mononuclear cells of 6 malaria-exposed Kenyan donors, Donor 8–13 were tested in parallel ex-vivo IFN-
(left), IL-4 (middle) and IL-10 (right) ELISPOT assays to MSP1 allelic variant peptide pairs (MAD20/WELLCOME), M3/M4, M5/M6, and
M7/M8. Lymphokine responses were expressed as positive SFU per million less the control SFU. Significant (P  0.05) responses are marked
with asterisks.
It was interesting to speculate whether the high MSP1
reactivity and pattern of distribution of allelic variant spe-
cific immune responses were specific to The Gambia. A dif-
ferent pattern of reactivity might be expected in Kenya, since
MSP1 allele frequencies in East Africa are different; equal
frequencies of MAD20 and WELLCOME allelic types have
been observed in Sudan.25
MSP1 peptides (M19 to M42) were tested in pools of
peptides (Table 1) in early IFN- ELISPOT assays in 58
Kenyan malaria-exposed adults. Only limited IFN- reactiv-
ity was observed in this population (Kenyan: MAD20 re-
sponses: 6.0%  2.5 SE and WELLCOME responses: 8.6%
 2.8 SE) compared to Gambian reactivity to these epitopes
(M19 to M42) (Gambian: MAD20 responses: 36.8%  1.7
SE and WELLCOME responses: 24.6%  2.5 SE). Parasite
typing of MSP1 strain distribution in  200 Kenyans with
clinical malaria showed a significant (chi-square, P 
5108) difference in distribution of MAD20 and WELL-
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TABLE 3
Summary of dry season IFN- reactivity to MSP1 allelic variant peptide pairs (M3/M4, M5/M6 and M7/M8) in malaria-exposed donors in
The Gambia and Kenya
Gambia reactivity Kenya reactivity
M3/M4
Peptide M3
Peptide M4
Specific (MAD20 versus WELLCOME)†
Both variants‡
10/20 (50%)*
10/20 (50%)*
9% versus 18%
73%
3/30 (10%)*
2/30 (7%)*
33% versus 0%
67%
M5/M6
Peptide M5
Peptide M6
Specific (MAD20 versus WELLCOME)†
Both variants‡
10/19 (53%)*
6/19 (48%)*
40% versus 0%
60%
1/31 (3%)*
3/31 (10%)*
0% versus 67%
33%
M7/M8
Peptide M7
Peptide M8
Specific (MAD20 versus WELLCOME)†
Both variants‡
4/19 (21%)*
11/19 (57%)*
0% versus 64%
36%
1/31 (3%)*
4/31 (13%)*
0% versus 75%
25%
* Percentages shown indicate the percentage of positive responders in each group.
† Percentage of specific responses induced by either the MAD20 or the WELLCOME variant from the total number of positive responders.
‡ Percentage of responses induced to both the MAD20 and the WELLCOME variant from the total number of positive responders.
COME in Kenya compared to The Gambia. The general pat-
tern of T-cell reactivity in Kenyan donors (Table 3, Figure
3) reflected the local parasite strain distribution (MAD20:
68%, WELLCOME: 32%).
T-cell responses to MSP1 in East Africa may be Th2 me-
diated with concomitant down-regulation of IFN- respons-
es. To address this possibility, the peptide pools were tested
for early IFN- and IL-4 secretion in parallel in another sev-
en exposed Kenyan donors. Figure 3A shows that few IL-4
responses were observed. In another six Kenyan donors test-
ed for early Th1 (IFN-) and Th2 (IL-4 and IL-10) produc-
tion assays to M3, M4, M5, M6, M7, and M8, no increase
in Th2 responses over Th1 responses by assessing either
lymphokine was observed in Kenya compared to The Gam-
bia (Figure 3B). Therefore, the lower MSP1 reactivity in
Kenya assessed by IFN- release was unlikely to be due to
cross-regulation by Th2 responses to these epitopes.
In The Gambia, the allelic IFN- T-cell responses to the
three variant pairs either followed (M5/M6) or failed to re-
flect (M3/M4, M7/M8) parasite prevalence. Whether differ-
ences in MSP1 parasite distribution could affect T-cell allelic
reactivity patterns were characterized in thirty Kenyan ma-
laria-exposed individuals (Table 3). In general, there was a
lower IFN- responder rate to these allelic pairs in Kenya
than in The Gambia (paired t-test, P  1103) (Table 3).
Moreover, in Kenya, allelic pair M3/M4 gave slightly higher
reactivity to MAD20 (M3:60% versus M4:40%). In contrast,
both allelic pairs of M5/M6 and M7/M8 gave higher reac-
tivity to the WELLCOME allelic type (M5:25% versus M6:
75%, M7:20% versus M8:80%). Thus, similar to data in The
Gambia, there was a heterogeneity in the prevalence of
MAD20 or WELLCOME responses in the three allelic var-
iant epitopes, with only some epitope-specific responses fol-
lowing East African parasite prevalence.
Similar broad reactivity (responses to both allelic forms)
patterns to the allelic pairs M3/M4, M5/6, and M7/8 in The
Gambia and Kenya were observed (Table 3). However, a
discordance between allelic specific responses and MSP1
parasite strain distribution was observed. Thus, only variant
specific responses to M5/M6 reflected the epidemiological
distribution of MSP1 alleles in both West and East Africa
with a prevalence of M5 (MAD20) responses in The Gambia
and higher M6 (WELLCOME) responses in Kenya. In con-
trast, allelic pair M3/M4 gave higher specific responses to
M4 (WELLCOME) in The Gambia and a higher response
to M3 (MAD20) in Kenya, in contrast to the expected epi-
demiological data. Surprisingly, the allelic pair M7/M8 had
higher specific responses to the WELLCOME allele in both
The Gambia and Kenya, independent of geographical dif-
ferences in MSP1 allelic distribution. Thus, in this analysis
of MSP1 allelic responses in two different populations in
distinct geographical areas, IFN- effector T-cell function to
certain allelic T-cell epitopes failed to reflect MSP1 epide-
miological distribution.
DISCUSSION
T-cell production of IFN- has been implicated in protec-
tive immunity to blood-stage malaria.11,16,17 IFN- can acti-
vate non-lymphocytic effector cells such as monocytes34,35 to
control parasite growth through phagocytosis,36 generate re-
active oxygen intermediates37 or L-arginine-derived nitric
oxide.38,39 However, IFN- does not control parasite growth
by direct elimination of intra-erythrocytic parasites.40–42 In
the present study, frequently recognized T-cell epitopes of
MSP1 distributed throughout the protein were identified in
naturally exposed malaria adults in The Gambia. The level
of IFN- reactivity ( 80%) to MSP1 epitopes was consid-
erably higher than in previous proliferative studies of this
antigen (range 30% to 40%) in naturally exposed West Af-
rican donors.11,16,17 This level of immune reactivity was in-
dependent of blood-sampling between dry and wet seasons
(data not shown). The use of selected peptides with high
binding potential to protective African alleles, or the detec-
tion of T cells with a different phenotype, i.e., rapid IFN-
production, may explain this higher level of reactivity. In-
terestingly, IFN- T cell reactivity to MSP1 ( 80%) was
higher than to the liver-stage antigens circumsporozite (CS)
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protein (20%) and thrombospondin-related anonymous pro-
tein (TRAP) (30%) tested in the same population (Flanagan
KL and others, unpublished data). It remains to be deter-
mined whether this represents a general difference in re-
sponse rate between blood-stage and pre-erythrocytic anti-
gens. Since cells from individuals not exposed to malaria
did not produce significant amounts of IFN-, it can be in-
ferred that malaria exposure was required to observe this
reactivity.
The extensive IFN- reactivity to these epitopes in The
Gambia supports the view that MSP1 is a major blood-stage
antigenic target which may play a significant role in IFN-
mediated protection in vivo. In murine studies, IFN- se-
creting T cell clones have been shown to be protect against
malaria by a nitric-oxide dependent mechanism43 which may
be dependent on macrophages and neutrophils.36,37 Alterna-
tively, T-cell secretion of IFN- may help in the induction
of protective cytophilic MSP1 IgG blood-stage specific an-
tibodies44 and may assist in antibody-dependent cellular in-
hibitory mediated mechanisms.45 In recent prospective case-
control studies of African children, IFN- responses to mer-
ozoite antigens were associated with resistance to malaria
reinfection.46
T-cell reactivity in the P. falciparum pre-erythrocytic an-
tigen, the circumsporozoite (CS) protein is focused on two
immunodominant epitope regions at its highly polymorphic
carboxyl terminus.47 No previous study has characterized im-
munodominance in the MSP1 protein. Such efforts may help
in the identification of potential polymorphic regions under
selection immune pressures.48,49 Recently, such polymorphic
epitopes in the CS protein have been shown to mutually
inhibit both T-cell priming50 and effector responses.32,51 Such
regions could be excluded from future blood-stage vaccines.
Here, MSP1 epitopes were distributed along the entire pro-
tein with no immunodominant regions. This suggests that
multiple fragments of the MSP1 protein, both shed before
and during RBC invasion52 can be processed and presented
to induce effector T cells.
It was surprising to observe overall lower levels of
MSP1 reactivity in Kenya (27%, 8 of 31 positive IFN- re-
sponders) than The Gambia ( 80%), given the higher ma-
laria transmission rate in the former.27 It could be argued that
immunosuppression due to malaria parasitemia may be re-
sponsible.53 However, this was unlikely since (i) all Kenyan
adults were negative for malaria parasites and (ii) statistical
analysis of Gambian IFN- reactivity patterns showed no
difference between samples collected during the wet and dry
seasons (data not shown).
It could be that low levels of reactivity to MSP1 simply
reflect low rates of IFN- responsiveness in East Africa com-
pared to West Africa. However, T cell reactivity to the P.
falciparum pre-erythrocytic antigens, CS protein and TRAP,
showed a similar response rate (30% in both locations) and
a doubling of IFN- responses in Kenya (60%) compared to
The Gambia (30%), respectively (Flanagan KL and Pleban-
ski M, unpublished data). The same reagents and peptide
batches were utilized when testing donors from The Gambia
or Kenya, or control malaria-unexposed donors in Oxford.
Since the testing of IFN responses to CS protein, TRAP,
and MSP1 responses was performed using the same assay
and on the same donors both in The Gambia and Kenya, the
lower reactivity to MSP1 in Kenya cannot be due to a gen-
eral suppression of IFN responses or assay differences. In-
terestingly, the general pattern of IFN- allelic T-cell reac-
tivity to MSP1 in 58 Kenyan adults was consistent with
MSP1 parasite strain distribution in East Africa. By contrast,
MSP1 peptide specific IFN- responses in The Gambia did
not show the expected excess of MAD20 over WELLCOME
reactivity.24 Therefore, MSP1 immune reactivity in The
Gambia may be regulated independently of antigenic expo-
sure.
Malaria-exposed donors could respond to different MSP1
epitopes either by IFN- or IL-4 release. Thus, IL-4 T-cell
production did not prevent IFN- release to other epitopes
and 58% of positive IL-4 responses also had IFN- respons-
es to the same epitopes, suggesting a Th1/Th-0 profile. In-
dependent IFN- or IL-4 production to different MSP1 epi-
topes was also observed in Kenya where responses were
either Th1 or Th2 specific. Interestingly, there was a sepa-
ration of Th2 responses into either IL-4 or IL-10 producing
epitopes. Thus, MSP1 epitopes can induce independent T-
cell production of Th1 or Th2 lymphokines. This indepen-
dent immune regulation of IFN- and IL-4 responses was
also reflected in the distribution of allele-specific T-cell re-
sponses to dimorphic epitopes. IL-4 responses in Kenyan
donors, although found less frequently than IFN- in The
Gambia, did follow the expected MAD20 prevalence.
It is not clear whether dimorphism in the MSP1 protein
enables the parasite to evade variant-specific acquired im-
mune responses. If this was the case, then such dimorphic
epitopes might indeed have levels of immune responses that
are not reflective of MSP1 parasite strain prevalence. Char-
acterization of allele specific IFN- responses to allelic
MSP1 T-cell epitopes suggests that mechanisms other than
parasite strain frequency-dependent immune selection54 may
influence reactivity patterns. We speculate that immune eva-
sion focused on IFN- responses to allelic-altered peptide
ligands of MSP1 may underlie the evolution of MSP1 di-
morphism.
In conclusion, frequently recognized T-cell epitopes have
been identified distributed throughout the P. falciparum
MSP1 with no immunodominant region. IFN- and IL-4 pro-
duction were independently regulated and IFN- allelic T-
cell reactivity patterns were discordant with epidemiological
parasite allelic prevalence for specific MSP1 epitopes. These
results suggest that MSP1 dimorphism may have evolved to
evade Th1 T-cell responses. Further understanding of the
immunological-selection pressure(s) that maintain MSP1 di-
morphism will be required before deployment of candidate
MSP1 vaccines in the field.
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